Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial

Stock Information for Quantum Biopharma Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Quantum Biopharma Ltd.

Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating 'Rare Moment' in MS Research
Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange
Quantum Biopharma Provides Corporate Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.